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Background: Randomized trials and recent meta-analyses document 
modest survival beneﬁts of novel two-drug chemotherapy regimens in 
the palliative care of patients with advanced non-small cell lung cancer 
(NSCLC). However, clinicians and health care policy-makers need 
to know whether similar survival beneﬁts also can be achieved in the 
unselected NSCLC patient population as a whole. 
We investigated therefore the geographical and timely variation of cy-
totoxic drug utilization in Norway and their associations with survival 
of NSCLC patients. Nearly 2200 cases of lung cancer are registered 
annually among the 4.6 million inhabitants of Norway. Chemotherapy 
in this setting was generally introduced around 1998, most commonly 
vinorelbin combined with carboplatin. 
Methods: We included all patients with advanced NSCLC diagnosed 
during 1994-2005 from the Cancer Registry of Norway. Vinorelbin was 
chosen as indicator drug for chemotherapy utilisation because of its 
exclusive use in NSCLC. Based on sales in grams that were obtained 
from the National Institute of Public Health we calculated population 
based utilization rates for each of the 19 counties in Norway. These 
rates were entered in a Cox-regression model as county characteris-
tics to estimate associations with survival. Furthermore we compared 
overall survival before and after the implementation of chemotherapy 
in Norway in 1998. 
Results: Of 20439 registered cases of NSCLC 13757 had advanced 
disease (see table for characteristics).
Patient characteristics %
Age (mean years) 67.5
Men 65.1
Squamous cell carcinoma 28.5
Adenocarcinoma 38.5
Non-speciﬁed 26.5
Condensed TNM  
Regional advanced 27.5
Metastatic 61.2
Others 11.4
Figure: Survival of patients with advanced NSCLC before and after the intro-
duction of modern chemotherapy in Norway
Median survival was 140 and 171 days during 1994-98 and 1999-2005, 
respectively (log-rank p <. 001). The corresponding hazard ratio was 
.91 (95% CI .86-.97) in favour of a diagnosis during the latter period. 
Annual utilisation rates of vinorelbin varied 5- to 7-fold between counties 
and they were inversely associated with the risk of death (HR .81 95% CI 
.7-.94). This association was not present for gemcitabine (HR .98 95% CI 
.94-1.01) which is rarely used against lung cancer in Norway.
Conclusion: This national study shows increasing survival of patients 
with advanced NSCLC during 1994-2005. Higher utilisation rates of 
a novel cytotoxic drug such as vinorelbin were clearly associated with 
increased survival. Differences of drug utilisation between counties 
should be minimized to achieve similar positive survival beneﬁts for all 
patients in Norway.
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ABT-869, a multiple tyrosine kinase inhibitor, has promising 
activity in patients with non-small cell lung cancer (NSCLC) in a 
phase I dose escalation study
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Background: Angiogenesis plays a major role in lung tumorigenesis 
and represents an ideal therapeutic target. ABT-869 is a novel, potent 
inhibitor of the vascular endothelial growth factor (VEGF) and platelet 
derived growth factor receptor tyrosine kinases. A phase I study of 
orally administered ABT-869 was performed to evaluate the maximal-
tolerated dose (MTD), safety, pharmacokinetics (PK) and pharmacody-
namics.
Methods: Patients with advanced refractory solid tumors received 
ABT-869 continuous once daily at night in 3-week cycles. Dose escala-
tion was planned in cohorts of 3 patients each and cohort expansion to 
6 patients was planned if dose-limiting toxicity (DLT) occurred in the 
ﬁrst cycle of treatment. MTD was deﬁned as the dose at which ≥2/6 pa-
tients encountered DLT. PK analysis was performed on days 1 and 15. 
Effects on the VEGF pathway were evaluated by circulating endothelial 
cells, and plasma VEGF. Microcirculatory parameters (blood ﬂow, 
capillary permeability and Ktrans) were assessed with DCE-MRI at 
baseline, days 3 and 14 of cycle 1. Adverse events were deﬁned accord-
ing to the CTC v3.0 and tumor response was evaluated with CT scans 
every 6 weeks according to RECIST criteria.
Results: 5 patients (median age 73 years) with NSCLC have been 
enrolled to date. The median number of prior treatments received 
was 2 (range 1-3). A total of 27 cycles of treatment was administered. 
Drug accumulation was not signiﬁcant with continuous dosing. Partial 
response was seen in 2/5 patients. The remaining 3 patients had stable 
disease including one patient with a 27% reduction in tumor size. CT 
scan evidence of cavitation and/ or necrosis of pulmonary disease was 
observed in 4/5 patients. Median time to progression was 11 weeks 
(range 5-35). Study treatment was discontinued in three patients 
